Shandong Zibo Xinda Pharmaceutical Co., Ltd.
-
Founded in:
1993-03-11 -
Country:
China -
Address:
No. 1, Lutai Avenue, Zibo High-tech Zone -
Tax NO.:
9137030361328152XT -
Registered Funds:
84.93 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Cefaclor |
This product is a broad-spectrum semi-synthetic cephalosporin antibiotic. Its activity against penicillinase-producing Staphylococcus aureus, group A hemolytic streptococci, viridans streptococci and Staphylococcus epidermidis is the same as that of cefadroxil, and its antibacterial effect against non-enzyme-producing Staphylococcus aureus and pneumococci is 2 to 4 times stronger than that of cefadroxil. Its activity against Gram-negative bacilli, including Escherichia coli and Klebsiella pneumoniae, is stronger than that of cefadroxil, and is similar to that of cefadroxil. Its activity against Proteus mirabilis, Salmonella and Shigella is stronger than that of cefadroxil. 2.9 to 8 mg/L of this product can inhibit all Haemophilus influenzae, including strains resistant to ampicillin. Moraxella catarrhalis and Neisseria gonorrhoeae are very sensitive to this product. Indole-positive Proteus, Serratia, Acinetobacter and Pseudomonas aeruginosa are all resistant to this product. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls.
More
This product is a broad-spectrum semi-synthetic cephalosporin antibiotic. Its activity against penicillinase-producing Staphylococcus aureus, group A hemolytic streptococci, viridans streptococci and Staphylococcus epidermidis is the same as that of cefadroxil, and its antibacterial effect against non-enzyme-producing Staphylococcus aureus and pneumococci is 2 to 4 times stronger than that of cefadroxil. Its activity against Gram-negative bacilli, including Escherichia coli and Klebsiella pneumoniae, is stronger than that of cefadroxil, and is similar to that of cefadroxil. Its activity against Proteus mirabilis, Salmonella and Shigella is stronger than that of cefadroxil. 2.9 to 8 mg/L of this product can inhibit all Haemophilus influenzae, including strains resistant to ampicillin. Moraxella catarrhalis and Neisseria gonorrhoeae are very sensitive to this product. Indole-positive Proteus, Serratia, Acinetobacter and Pseudomonas aeruginosa are all resistant to this product. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls. |
53994-73-3 | 29 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Cefradine |
This product is a first-generation cephalosporin, which has good antibacterial effect on some strains of Gram-positive cocci such as non-penicillinase-producing and penicillinase-producing Staphylococcus aureus, coagulase-negative Staphylococcus, group A hemolytic Streptococcus, Streptococcus pneumoniae and viridans Streptococcus. Anaerobic Gram-positive bacteria are mostly sensitive to this product, while Bacteroides fragilis is resistant to it. Methicillin-resistant Staphylococci and Enterococci are resistant to this product. The effect of this product on Gram-positive and Gram-negative bacteria is similar to that of cephalexin. This product has a certain effect on Neisseria gonorrhoeae, and is also active against enzyme-producing Neisseria gonorrhoeae; its activity against Haemophilus influenzae is poor.
More
This product is a first-generation cephalosporin, which has good antibacterial effect on some strains of Gram-positive cocci such as non-penicillinase-producing and penicillinase-producing Staphylococcus aureus, coagulase-negative Staphylococcus, group A hemolytic Streptococcus, Streptococcus pneumoniae and viridans Streptococcus. Anaerobic Gram-positive bacteria are mostly sensitive to this product, while Bacteroides fragilis is resistant to it. Methicillin-resistant Staphylococci and Enterococci are resistant to this product. The effect of this product on Gram-positive and Gram-negative bacteria is similar to that of cephalexin. This product has a certain effect on Neisseria gonorrhoeae, and is also active against enzyme-producing Neisseria gonorrhoeae; its activity against Haemophilus influenzae is poor. |
38821-53-3 | 27 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Cefaclor |
Antibacterial drug. The beta-lactamase produced by Staphylococcus aureus is relatively stable, so it has a strong antibacterial effect on Gram-positive bacteria; the beta-lactamase produced by Gram-negative bacteria is unstable, so it has a weaker effect on Gram-negative bacteria and is ineffective against Pseudomonas aeruginosa and anaerobic bacteria.
More
Antibacterial drug. The beta-lactamase produced by Staphylococcus aureus is relatively stable, so it has a strong antibacterial effect on Gram-positive bacteria; the beta-lactamase produced by Gram-negative bacteria is unstable, so it has a weaker effect on Gram-negative bacteria and is ineffective against Pseudomonas aeruginosa and anaerobic bacteria. |
53994-73-3 | 29 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Cefixime |
This product is an oral third-generation cephalosporin with a broad antibacterial spectrum. It has antibacterial activity against some Gram-positive and Gram-negative bacteria, especially against Streptococcus (except Enterococcus) and Pneumococcus among Gram-positive bacteria, and gonococci, Branhamella, Escherichia coli, Klebsiella, Serratia, Proteus, and influenza bacilli among Gram-negative bacteria. Its mechanism of action is to prevent the synthesis of bacterial cell walls, and it has a high affinity with 1 (1a, 1b, 1c) and 3 in penicillin-binding protein (PBP), and it has strong stability against beta-lactamase produced by various bacteria, and shows excellent antibacterial power against bacteria producing beta-lactamase.
More
This product is an oral third-generation cephalosporin with a broad antibacterial spectrum. It has antibacterial activity against some Gram-positive and Gram-negative bacteria, especially against Streptococcus (except Enterococcus) and Pneumococcus among Gram-positive bacteria, and gonococci, Branhamella, Escherichia coli, Klebsiella, Serratia, Proteus, and influenza bacilli among Gram-negative bacteria. Its mechanism of action is to prevent the synthesis of bacterial cell walls, and it has a high affinity with 1 (1a, 1b, 1c) and 3 in penicillin-binding protein (PBP), and it has strong stability against beta-lactamase produced by various bacteria, and shows excellent antibacterial power against bacteria producing beta-lactamase. |
79350-37-1 | 49 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Ampicillin |
This product is a broad-spectrum semi-synthetic penicillin with extremely low toxicity. The antibacterial spectrum is similar to that of penicillin, and it has a strong antibacterial effect on grass-green streptococci, hemolytic streptococci, and enterococci. Diphtheria bacillus, anthrax bacillus, Gram-positive anaerobic cocci and bacilli are sensitive to this product; meningococci, pertussis bacilli, and Brucella are also very sensitive. Escherichia coli, Salmonella, Shigella dysenteriae, Proteus, influenza bacilli, pneumococci, gonococci, etc., all have varying degrees of drug resistance because some strains produce beta-lactamase. Among them, the resistance rate of Escherichia coli is as high as 50-60%. Enterobacter bacteria, Pseudomonas aeruginosa, and anaerobic Gram-negative bacilli are resistant to this product. This product is mainly used to treat infectious diseases caused by sensitive Staphylococcus aureus, hemolytic streptococci, gonococci, meningococci and diphtheria Bordetella, pertussis Bordetella, influenza Bordetella, Salmonella, Shigella, etc.; such as respiratory tract infections (pneumonia, acute and chronic bronchitis, whooping cough, etc.), gastroenteritis and digestive tract infections (liver and gallbladder infections, acute and chronic gastroenteritis, bacillary dysentery, typhoid and paratyphoid, etc.), urinary tract infections (gonorrhea, urethritis, cystitis, etc.), soft tissue infections and sepsis, meningitis, endocarditis, etc.
More
This product is a broad-spectrum semi-synthetic penicillin with extremely low toxicity. The antibacterial spectrum is similar to that of penicillin, and it has a strong antibacterial effect on grass-green streptococci, hemolytic streptococci, and enterococci. Diphtheria bacillus, anthrax bacillus, Gram-positive anaerobic cocci and bacilli are sensitive to this product; meningococci, pertussis bacilli, and Brucella are also very sensitive. Escherichia coli, Salmonella, Shigella dysenteriae, Proteus, influenza bacilli, pneumococci, gonococci, etc., all have varying degrees of drug resistance because some strains produce beta-lactamase. Among them, the resistance rate of Escherichia coli is as high as 50-60%. Enterobacter bacteria, Pseudomonas aeruginosa, and anaerobic Gram-negative bacilli are resistant to this product. This product is mainly used to treat infectious diseases caused by sensitive Staphylococcus aureus, hemolytic streptococci, gonococci, meningococci and diphtheria Bordetella, pertussis Bordetella, influenza Bordetella, Salmonella, Shigella, etc.; such as respiratory tract infections (pneumonia, acute and chronic bronchitis, whooping cough, etc.), gastroenteritis and digestive tract infections (liver and gallbladder infections, acute and chronic gastroenteritis, bacillary dysentery, typhoid and paratyphoid, etc.), urinary tract infections (gonorrhea, urethritis, cystitis, etc.), soft tissue infections and sepsis, meningitis, endocarditis, etc. |
69-53-4 | 26 |